Arcus Biosciences, Inc. (RCUS)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-25) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-10-28) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-06) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-25) · 99.1 | 8-K (2025-02-18) | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-08) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-21) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Statements | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Operations (P) | ||
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Statements of Comprehensive Loss | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Business Segment | ||
| Cash, Cash Equivalents and Marketable Securities | ||
| Commitments | — |
|
| Consolidated Balance Sheet Components | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Defined Contribution Plan | — |
|
| Fair Value Measurements | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| License and Collaborations | ||
| Long-term Debt | ||
| Net Income (loss) Per Share | ||
| Net Loss Per Share | ||
| Organization, Liquidity and Capital Resources | ||
| Organization, Liquidity, and Capital Resources | — |
|
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Related Party | ||
| Related Party - Gilead Sciences, Inc. | — |
|
| Revenues | ||
| Segments of Business | — |
|
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Events | — |
|
| Summary of Significant Accounting Policies | ||